AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
— Collaboration leveragesAbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform — Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B AbbVie (NYSE: ABBV) and Neomorph, Inc.today announced a collaboration and option-to-license agreement to develop novel molecular glue […]